Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Jeffrey J. Wisnieski is active.

Publication


Featured researches published by Jeffrey J. Wisnieski.


Journal of Immunology | 2001

The Globular Heads of C1q Specifically Recognize Surface Blebs of Apoptotic Vascular Endothelial Cells

Jeannine S. Navratil; Simon C. Watkins; Jeffrey J. Wisnieski; Joseph M. Ahearn

Complement protein C1q is required to maintain immune tolerance. The molecular mechanism responsible for this link has not been determined. We have previously demonstrated that C1q binds directly and specifically to surface blebs of apoptotic human keratinocytes, suggesting that it may participate in clearance of self Ags generated during programmed cell death. Here, we demonstrate that C1q also binds directly to apoptotic blebs of vascular endothelial cells and PBMC. These apoptotic cells are recognized by the globular heads of C1q, which bind specifically to the surface blebs, and deposition increases as the blebs mature on the cell surface. These observations suggest that C1q may participate in the clearance of apoptotic cells from the circulation and from the walls of the vascular lumen. The interaction of surface blebs with the globular heads of C1q suggests that surface blebs may be capable of directly activating the classical pathway of complement under certain circumstances, generating C4- and C3-derived ligands for receptors such as CR1, CR2, CR3, and CR4. Appropriate recognition of apoptotic cells by C1q and targeted clearance of the molecular contents of surface blebs to complement receptors may be critical for the maintenance of immune tolerance.


Medicine | 1995

Hypocomplementemic urticarial vasculitis syndrome: Clinical and serologic findings in 18 patients

Jeffrey J. Wisnieski; Alan N. Baer; Jim Christensen; Thomas R. Cupps; Douglas N. Flagg; John Verrier Jones; Paul L. Katzenstein; E. R. Mcfadden; James J. Mcmillen; Michael A. Pick; Wendell G. Richmond; Sanford R. Simon; Howard R. Smith; Richard D. Sontheimer; Laura B. Trigg; David Weldon; John J. Zone

We identify and describe clinical findings in hypocomplementemic urticarial vasculitis syndrome (HUVS), an uncommon to rare illness related to systemic lupus erythematosus (SLE). A patient with recurrent, idiopathic urticaria-like lesions was diagnosed as having HUVS if a lesional biopsy showed leukocytoclastic vasculitis, the serum C1q was markedly decreased, and antibody to C1q was detected in the patients serum. The clinical characteristics, serologic findings, and outcome of patients who met these criteria were determined from prospective and retrospective data, including hospital and office records, patient interviews, previously banked serum samples, and freshly drawn sera. Eighteen patients with HUVS were identified, and high incidences of angioedema, ocular inflammation, glomerulonephritis, and obstructive pulmonary disease were found. Renal and lung biopsies showed mesangial or membranoproliferative glomerulonephritis and severe pulmonary emphysema without vasculitis. Pulmonary function was measured in 17 patients, 11 of whom had dyspnea. All dyspneic patients had moderate to severe airflow obstruction, which progressed in all 11 and subsequently improved in only 1. Six of these 11 patients died of respiratory failure, 1 underwent lung transplantation, and 3 of the remaining 4 have moderately severe to life-threatening respiratory insufficiency. Treatment did not appear to alter the progression of obstructive lung disease. In contrast, renal insufficiency improved with treatment in 2 of 2 patients. Angioedema, ocular inflammation, obstructive lung disease, and glomerulonephritis appear to be common in HUVS, and lung disease causes substantial morbidity and mortality. The pathogenesis of HUVS may involve humoral autoimmunity, although it is not clear how autoimmunity would participate in development of obstructive lung disease. Cigarette smoking appears to be a risk factor for fatal lung disease in HUVS. All patients with HUVS should be made aware of this possibility and should be advised, encouraged, and helped to avoid tobacco smoke.


Journal of Clinical Investigation | 1996

Induction of monocyte expression of tumor necrosis factor alpha by the 30-kD alpha antigen of Mycobacterium tuberculosis and synergism with fibronectin.

Htin Aung; Zahra Toossi; Jeffrey J. Wisnieski; Robert S. Wallis; Lloyd A. Culp; Nelson B. Phillips; Manijeh Phillips; Lynn E. Averill; Thomas M. Daniel; Jerrold J. Ellner

Native 30-kD antigen, also known as alpha antigen, is a fibronectin-binding protein that is secreted by live Mycobacterium tuberculosis. This antigen may play an important biological role in the host-parasite interaction since it elicits delayed type hypersensitivity response and protective immunity in vivo and T lymphocyte blastogenesis and IFN-gamma production in vitro. In the present study, we show that, TNF-alpha protein is produced in monocyte culture supernatants in response to 30-kD antigen and the level is as high as that to purified protein derivative of M. tuberculosis. This stimulatory effect was not due to contamination with either bacterial lipopolysaccharide or mycobacterial lipoarabinomannan. The preincubation of monocytes with plasma fibronectin significantly enhanced the release of TNF-alpha into the culture supernatants in response to 30-kD antigen. This effect was blocked by polygonal antibody to plasma fibronectin. In contrast, the monocytic cell line U937 failed to release TNF-alpha protein in the culture supernatants in response to 30-kD antigen with or without preincubation with plasma fibronectin. To determine whether this observation was due to differential binding of the 30-kD to fibronectin on these cells, a cell based ELISA was used. Pretreatment of monocytes with fibronectin enhanced their binding of the 30-kD antigen. U937 cells bound the 30-kD antigen weakly with or without fibronectin pretreatment. These results indicate that 30-kD antigen which is a known secretary antigen of M. tuberculosis is a stimulus for human monocytes to express TNF-alpha and that stimulatory effect may be mediated through plasma fibronectin.


The Journal of Pediatrics | 1994

Hypocomplementemic urticarial vasculitis syndrome with severe systemic manifestations.

Alberto Martini; Angelo Ravelli; Salvatore Albani; Fabrizio De Benedetti; Margherita Massa; Jeffrey J. Wisnieski

We describe two children with clinical and laboratory features of hypocomplementemic urticarial vasculitis syndrome. Both patients had severe, life-threatening manifestations: rapidly progressive glomerulonephritis (patient 1) and pulmonary hemorrhage (patient 2). We conclude that this syndrome may be a potentially severe multisystem disease.


Journal of Clinical Investigation | 1984

Inherited incomplete deficiency of the fourth component of complement (C4) determined by a gene not linked to human histocompatibility leukocyte antigens.

W A Muir; S Hedrick; Chester A. Alper; O D Ratnoff; B Schacter; Jeffrey J. Wisnieski

We have studied a family in which the proband had systemic lupus erythematosus and selective incomplete deficiency of the fourth component of complement (C4) (2-5% of the normal level). An additional six healthy family members also had low C4 levels (2.4-24.1% of normal) but no evidence of lupus. This form of inherited C4 deficiency differs from that in previously reported families in that inheritance was autosomal dominant (rather than recessive), C4 levels were markedly reduced (but not undetectable), and there was no linkage to HLA, BF, or C4 structural loci, all known to be within the major histocompatibility complex.


Journal of Immunology | 2001

C1 Inhibitor: Analysis of the Role of Amino Acid Residues Within the Reactive Center Loop in Target Protease Recognition

Rana Zahedi; Ryan C. MacFarlane; Jeffrey J. Wisnieski; Alvin E. Davis

Previous analysis of a naturally occurring C1 inhibitor P2 mutant (Ala443→Val) indicated a role for P2 in specificity determination. To define this role and that of other reactive center loop residues, a number of different amino acids were introduced at P2, as well as at P6 (Ala439) and P8′/9′ (Gln452Gln453). Ala439→Val is a naturally occurring mutant observed in a patient with hereditary angioedema. Previous data suggested that Gln452Gln453 might be a contact site for C1s. Reactivity of the inhibitors toward target (C1s, C1r, kallikrein, β factor XIIa, and plasmin) and nontarget proteases (α-thrombin and trypsin) were studied. Substitution of P2 with bulky or charged residues resulted in decreased reactivity with all target proteases. Substitution with residues with hydrophobic or polar side chains resulted in decreased reactivity with some proteases, but in unaltered or increased reactivity with others. Second order rate constants for the reaction with C1s were determined for the mutants with activities most similar to the wild-type protein. The three P2 mutants showed reductions in rate from 3.35 × 105 M−1s−1 for the wild type to 1.61, 1.29, and 0.63 × 105 for the Ser, Thr, and Val mutants, respectively. In contrast, the Ala439→Val and the Gln452Gln453→Ala mutants showed little difference in association rates with C1s, in comparison with the wild-type inhibitor. The data confirm the importance of P2 in specificity determination. However, the P6 position appears to be of little, if any, importance. Furthermore, it appears unlikely that Gln452Gln453 comprise a portion of a protease contact site within the inhibitor.


Journal of Immunology | 1997

Role of the P2 residue of complement 1 inhibitor (Ala443) in determination of target protease specificity: inhibition of complement and contact system proteases.

Rana Zahedi; Jeffrey J. Wisnieski; Alvin E. Davis


Journal of Immunology | 1994

Unique C1 inhibitor dysfunction in a kindred without angioedema. I. A mutant C1 INH that inhibits C1-s but not C1-r.

Jeffrey J. Wisnieski; Thomas C. Knauss; Iwona Yike; Dorr G. Dearborn; Rebecca L. Narvy; George B. Naff


Southern Medical Journal | 1995

Sarcoid myopathy in a patient with human immunodeficiency virus infection.

Janice Granieri; Jeffrey J. Wisnieski; Richard C. Graham; Howard R. Smith; Prema Gogate; John N. Aucott


The American review of respiratory disease | 1985

Immune complexes and complement abnormalities in patients with cystic fibrosis. Increased mortality associated with circulating immune complexes and decreased function of the alternative complement pathway

Jeffrey J. Wisnieski; Earl W. Todd; Fuller Rk; Jones Pk; Dorr G. Dearborn; Thomas F. Boat; George B. Naff

Collaboration


Dive into the Jeffrey J. Wisnieski's collaboration.

Top Co-Authors

Avatar

George B. Naff

Case Western Reserve University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Dorr G. Dearborn

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Howard R. Smith

Case Western Reserve University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Thomas F. Boat

University of Cincinnati

View shared research outputs
Top Co-Authors

Avatar

Thomas M. Daniel

Case Western Reserve University

View shared research outputs
Top Co-Authors

Avatar

Alan N. Baer

Johns Hopkins University School of Medicine

View shared research outputs
Researchain Logo
Decentralizing Knowledge